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Abstract
Introduction Extended adjuvant endocrine therapy for breast
cancer with aromatase inhibitors may potentially alter the lipid
profile of postmenopausal patients and thus increase the risk of
developing cardiovascular disease. In this study, a subprotocol
of the ATENA (Adjuvant post-Tamoxifen Exemestane versus
Nothing Applied) trial, we compared the effect of the steroidal
aromatase inactivator exemestane on the lipid profile of
postmenopausal patients with operable breast cancer, in the
adjuvant setting, with that of observation alone after completion
of 5 to 7 years of primary treatment with tamoxifen.
Methods In this open-label, randomized, parallel-group study,
411 postmenopausal patients with operable breast cancer, who
had been treated with tamoxifen for 5 to 7 years, were
randomized to either 5 additional years of exemestane (25 mg/
day; n = 211) or observation only (n = 200). Assessments of
total cholesterol (TC), high-density lipoprotein (HDL), low-
density lipoprotein (LDL), and total serum triglycerides (TRG)
were performed at baseline and then during each follow-up visit,
performed at either 6 or 12 months, according to the center's
clinical practice, until completing 24 months in the study.
Results TC and LDL levels increased significantly across time
for both arms; TC increase was more pronounced for the
observation arm, and that was sustained up to 24 months. HDL
levels decreased significantly across time for the exemestane
arm, whereas no significant change was detected across time
for the observation arm. Triglyceride levels decreased
significantly across time on both arms, with no difference
detected in changes from baseline between the exemestane
and the observation arms.
Conclusions Exemestane lacks the beneficial effect of
tamoxifen on lipids; however, sequential adjuvant treatment with
exemestane in postmenopausal breast cancer patients after
cessation of 5 to 7 years of tamoxifen does not appear to alter
the lipid profile significantly compared with that of an
observational arm.
Trial Registration ClinicalTrials.gov ID: NCT00810706.
Introduction
The primary objective of the adjuvant hormonal treatment is to
reduce risk of recurrence and therefore increase overall sur-
vival. In postmenopausal women, the two most commonly
used strategies of endocrine treatment are either the interfer-
ence with estrogen signaling by binding to the estrogen-
receptor protein with a selective estrogen-receptor modulator
ABCSG: Austrian Breast and Colorectal Cancer Study Group; AI: aromatase inhibitor; ATENA: Adjuvant post-Tamoxifen Exemestane versus Nothing 
Applied trial; E: exemestane; EBCTCG: Early Breast Cancer Trialists' Collaborative Group; ECOG: Eastern Cooperative Oncology Group; HDL: high-
density lipoprotein; HRT: hormone replacement therapy; LEAP: The Letrozole, Exemestane and Anastrozole Pharmacodynamics trial; LDL: low-density 
lipoprotein; MBC: metastatic breast cancer; NSABP: National Surgical Adjuvant Breast and Bowel Project; O: observation; SERM: selective estro-
gen-receptor modulator; TC: total cholesterol; TEAM: Tamoxifen and Exemestane Adjuvant Multicenter trial; TRG: total serum triglycerides.Breast Cancer Research    Vol 11 No 3    Markopoulos et al.
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(SERM), such as tamoxifen, or the inhibition of endogenous
estrogen production by using an aromatase inhibitor (AI).
Tamoxifen has been the standard adjuvant endocrine therapy
for postmenopausal women with breast cancer for more than
30 years; however, its use in recent years has been ques-
tioned after indication of an increased risk of endometrial can-
cer, thromboembolic events, and tolerability concerns [1].
These risks are considered to be a consequence of tamoxifen
partial estrogen-agonistic effect. These limitations, along with,
most important, the development of resistance, urged the
expansion of different approaches in the systemic adjuvant
treatment of breast cancer. Notably, fulvestrant, a novel estro-
gen-receptor antagonist that produces complete receptor
blockade and has no estrogen-agonistic activity, is currently
licensed only for the treatment of advanced breast cancer after
recurrence or progression with prior endocrine therapy [2,3].
More recently, inhibition of aromatase, the enzyme that con-
verts androgens to estrogens, with agents including anastro-
zole, letrozole, and exemestane, has been shown to be an
effective alternative to tamoxifen for postmenopausal women
with hormone-dependent breast cancer. Treatment with AIs
produces frequent and durable responses in postmenopausal
women previously treated with tamoxifen or endocrine ablative
surgery, and AIs are more effective than tamoxifen in produc-
ing responses and delaying progression in first-line treatment
of metastatic disease [4,5].
Clinical trials established the role of AIs in the adjuvant therapy
for postmenopausal women with hormone-responsive breast
cancer in upfront, switch, and sequential treatment settings [6-
9], and this is reflected by international guidelines such as the
American Society of Clinical Oncology [10], St. Gallen [11],
National Comprehensive Cancer Network [12], and others.
The EBCTCG group was recently shown, through an overview
of the randomized trials, that more than 50% of disease recur-
rences occur after the end of 5 years of tamoxifen treatment,
possibly because of micrometastatic disease that may still be
present [13]. Extending tamoxifen use further than the stand-
ard 5-year duration of treatment has been proven to be ineffec-
tive [14]. Postmenopausal women with hormone receptor-
positive tumors who have completed about 5 years of adjuvant
tamoxifen therapy should be considered for treatment with an
AI. This strategy has been widely studied by the National Can-
cer Institute of Canada MA.17 [9], the Austrian Breast and
Colorectal Cancer Study Group (ABCSG) 6a [15], and the
NSABP B-33 [16] trials. The MA.17 trial was the first to dem-
onstrate that an AI in the extended adjuvant-treatment setting
was effective in reducing the risk for recurrence, and the first
results from ABCSG-6a and NSABP-33 further supported the
effectiveness of this treatment strategy.
However, a question exists on the long-term safety of these
agents, in particular with respect to the effects on the lipid pro-
files of postmenopausal women. Lipid-metabolism disorders
can be the cause of a wide range of conditions, with cardio-
vascular disease being the most significant [17,18]. Cardio-
vascular disease is the leading cause of death in the
developed world for women [19]. The role of low-density lipo-
protein cholesterol (LDL) in the pathogenesis of atherosclero-
sis and subsequently in coronary heart disease is well known.
Evidence suggests that increased levels of LDL are highly cor-
related with increased risk of heart disease, even while total
cholesterol remains within normal range [20]. At the same
time, high-density lipoprotein (HDL) cholesterol is known for
its protective effect against coronary heart disease [21]. The
role of triglycerides is less clear, but increased levels have
been associated with risk of cardiovascular diseases in both
women and men [22].
The risk of cardiovascular mortality increases dramatically in
women after menopause [22] because of lipid-metabolism
alterations that are attributed to estrogen deprivation. Levi et
al. [23] suggested that the greatest cause of death in women
with early-stage breast cancer is heart disease. Because of the
high levels of estrogen deprivation caused by aromatase inhib-
itors, the effect of such inhibition on lipid profiles and thus car-
diovascular disease [24-26] has been a concern, especially
considering the protective effects that tamoxifen exerts on lipid
profiles [27,28]. It is, therefore, necessary to study these
effects to assess efficiently the cost-to-benefit relation. How-
ever, we note that, in the extended adjuvant treatment setting,
the effect of aromatase inhibition on lipids should be com-
pared with the post-tamoxifen-deprivation lipid profile. The
tamoxifen beneficial effect on the lipid profile of postmenopau-
sal breast cancer patients seems to be lost in less than 12
months after cessation of tamoxifen treatment, and patients
are assumed to return within the ranges of the average post-
menopausal female population [29].
Exemestane is an irreversible steroidal inhibitor of aromatase
[30,31] that was recently shown to confer both an overall and
a disease-free survival advantage when given after 2 to 3 years
of tamoxifen compared with the standard 5 years of tamoxifen
in the adjuvant treatment of postmenopausal breast cancer
patients [8,32]. The Adjuvant post-Tamoxifen Exemestane ver-
sus Nothing Applied (ATENA) trial was an open-label rand-
omized parallel-group study of postmenopausal women with
operable breast cancer who had been treated with tamoxifen
for 5 to 7 years and then switched to exemestane or observa-
tion alone for 5 additional years. The ATENA lipid substudy
compared alterations in the lipid profile after initiation of
exemestane treatment with those of women who cease
tamoxifen treatment and thus lose the beneficial effect of
tamoxifen on lipids. Preliminary results have already been pub-
lished [33]. Here we report the analysis of the final results at
24 months of treatment.Available online http://breast-cancer-research.com/content/11/3/R35
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Materials and methods
The ATENA phase III randomized parallel-group multicenter
trial was designed to compare 5 years of adjuvant exemestane
with 5 years of observation in postmenopausal women with
operable breast cancer who had received 5 to 7 years of adju-
vant tamoxifen. Recruitment of 1,803 core patients was
planned in the ATENA trial from study sites of the Hellenic
Breast Surgeons Society. The primary end point for the core
protocol was disease-free survival (DFS). The lipid substudy
was designed to evaluate changes in the patients' serum lipid
profile during study treatment. The ATENA trial was prema-
turely discontinued because of the publication of the MA.17
trial results [9]. A total of 411 of 448 patients randomized in
the ATENA trial until closure were eligible for the lipid sub-
study. Exemestane treatment (25 mg/day) was planned for 5
years, unless disease relapse or excessive toxicity was docu-
mented, the patient refused further treatment, or any new anti-
cancer therapy was initiated.
All patients entering the substudy had no history of any con-
comitant disease that could affect the lipid profile, including
familial dyslipidemia. No reports of cholesterol-lowering agent
consumption existed in our concomitant-medication database.
Patients were not instructed to follow a specific diet during the
study; however, before offering a blood sample, all patients
were required to fast for 12 hours. Blood samples for lipid-pro-
file analysis (cholesterol, HDL, LDL, and total triglycerides)
were measured at baseline and then during each follow-up
visit, performed at either 6 or 12 months, according to the
standard clinical practice at each participating centre.
The study was approved by the relevant local institutional eth-
ics committees and was conducted according to the Declara-
tion of Helsinki. Informed-consent forms were accordingly
signed by all patients before entering randomization.
Statistical analysis
Descriptive statistics (mean, standard deviation) by treatment
group of all lipid variables and of corresponding differences
from baseline are presented for each visit. Mixed-effects mod-
els were used for estimating the time and treatment effects on
each of the four lipid parameters for the study duration. Com-
pound symmetry variance-covariance matrix and a random
intercept effect were used in these models. These polynomial
growth-curve models reliably explore trends across time and
between treatment groups, by taking into account the within-
subject variability and the common problem, in repeated-
measures data, of missing values [34]. The mixed-effects mod-
els were run both on the actual lipid parameter values and on
their logarithms. Estimations of absolute value means and
mean changes from baseline for each treatment arm at each
time point obtained from the appropriate mixed-effects model
are presented in tables and figures. Analysis was performed by
using the SAS statistical package (SAS Institute Inc., Cary,
NC, USA). All reported P values are two-sided, and results
were considered significant at α = 0.05.
Results
Four hundred forty-eight patients were randomized in the
ATENA trial from January 2001 until premature closure of the
trial on November 2005 due to poor recruitment, as a result of
the publication of the MA.17 trial results. Two recruiting cent-
ers did not participate in the lipid substudy, and 14 patients
were not eligible because of consumption of cholesterol-low-
ering agents. In total, 411 of 448 patients randomized in the
ATENA trial were eligible for the lipid substudy, with 211
patients randomized to the exemestane arm (E), and 200
patients, to the observation arm (O). This is the final report on
the analysis of data during the 2-year study period.
Patient characteristics, including age, weight at randomization,
prior adjuvant chemotherapy or radiotherapy, and ECOG per-
formance status are presented in Table 1. No significant differ-
ences were found between the two arms for any baseline
parameter. At 12 months, 162 patients had available measure-
ment for cholesterol level (90 in E and 72 in O), 107 for HDL
(59 in E, 48 in O), 97 for LDL (53 in E, 44 in O), and 144 for
triglyceride levels (84 in E and 60 in O). The corresponding
sample sizes at 24 months were 94 for the cholesterol level
(45 in E, 49 in O), 64 for HDL (27 in E, 37 in O), 64 for LDL
(26 in E, 38 in O) and 86 for Triglyceride levels (43 in E, 43 in
O).
Mean observed absolute values and corresponding standard
deviations (SDs) for each lipid parameter at baseline, at 1 year,
at 1.5 years, and at 2 years after baseline are presented in
Table 2, whereas mean observed changes from baseline val-
ues over the study period are presented in Table 3. The corre-
sponding differences between treatments of mean absolute
values over the study period, as estimated from the mixed-
effects models, are presented in Table 4.
Figure 1 shows, by treatment arm, the observed and the esti-
mated mean values for each lipid parameter across time.
Cholesterol for the first 18 months increased significantly
across time for both arms, an effect that is more pronounced
for the observation arm and is sustained up to 24 months (P =
0.0005, P = 0.019 for time and time-squared effect, respec-
tively; Tables 2 through 4). The corresponding estimated dif-
ferences between the E and O arms in absolute changes from
baseline were not significant across time (Table 4 and Figure
1).
The HDL levels decreased significantly across time for the
exemestane arm, whereas an increase was detected across
time for the observation arm, without reaching statistical signif-
icance (P = 0.08; Tables 2 through 4, Figure 1). The effect of
time was significantly different between treatment arms (treat-Breast Cancer Research    Vol 11 No 3    Markopoulos et al.
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ment group × time interaction, P value = 0.0012), with the
mean absolute HDL levels for the observation arm being con-
sistently higher across time than for the exemestane arm, and
the distance between them increasing with time (Table 4 and
Figure 1).
The LDL levels increased significantly across time (time P
value < 0.0001) similarly for both arms (treatment P value =
0.08), with an initial sharp increase diminishing up to the 18-
month time point, at which a trend reversal leading to smaller
mean values at 24 months is apparent (time-squared P value
< 0.0001; Tables 2 through 4). The corresponding estimated
mean differences between the E and O arms in absolute
Table 1
Patient characteristics
Exemestane Observation Total
Patients Number 211 200 411
Age Mean 62.6 61.8 62.2
(range) (40–81) (39–81) (39–81)
Weight Mean 71.8 69.6 70.6
(range) (48–100) (52–100) (48–100)
Adjuvant chemotherapy n (%)
No 131 (62.09) 121 (60.5) 252 (61.31)
Yes 80 (37.91) 79 (39.5) 159 (38.69)
Local radiation therapy n (%)
No 77 (36.49) 82 (41.0) 159 (38.69)
Yes 117 (55.45) 99 (49.5) 216 (52.55)
Missing data 17 (8.06) 19 (9.5) 36 (8.76)
ECOG performance status n (%)
0 164 (77.73) 148 (74.0) 312 (75.91)
1 33 (15.64) 41 (20.5) 74 (18.0)
2 1 (0.47) 0 (0.0) 1 (0.24)
Not reported 13 (6.16) 11 (5.5) 24 (5.84)
ER and PgR status n (%)
ER+/PgR+ 110 (52.13) 107 (53.5) 217 (52.8)
ER+/PgR- 23 (10.9) 19 (9.5) 42 (10.22)
ER-/PgR+ 13 (6.16) 10 (5.0) 23 (5.6)
ER+/PgR unknown 15 (7.11) 11 (5.5) 26 (6.33)
ER and PgR unknown 50 (23.7) 53 (26.5) 103 (25.06)
Table 2
Observed absolute values for lipid parameters [mg/dl] across the study period (mean ± standard error)
Cholesterol value HDL value LDL value Total triglycerides value
EO E O EO EO
Baseline 215 ± 3.4 217 ± 3.3 57 ± 1.3 57 ± 1.4 136 ± 4.5 133 ± 4.2 136 ± 6.1 135 ± 5.8
6 mo 227 ± 4.2 226 ± 5.8 56 ± 1.6 60 ± 1.5 149 ± 4.5 143 ± 7.3 116 ± 7 127 ± 7.8
12 mo 228 ± 4.2 231 ± 4.5 53 ± 1.4 60 ± 1.7 152 ± 4.9 145 ± 4.3 111 ± 5.5 117 ± 6
18 mo 234 ± 6 228 ± 6 51 ± 1.8 60 ± 2.1 161 ± 7.7 145 ± 6.8 121 ± 6.5 111 ± 9
24 mo 228 ± 5.6 230 ± 4.8 52 ± 1.9 62 ± 1.9 154 ± 6.3 136 ± 6.5 112 ± 6.5 118 ± 7.8
E = Exemestane; O = Observation.Available online http://breast-cancer-research.com/content/11/3/R35
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changes from baseline were constant across time, equal to
7.77 ± 4.42 mg/dl (Table 4 and Figure 1).
Triglyceride levels decreased significantly across time on both
arms, with no difference detected in changes from baseline
between E and O (Tables 2 through 4). Observed values show
a variable behavior, increasing or decreasing in adjacent time
points. The appropriate polynomial mixed-effect model was fit
on the logarithm of triglyceride levels (P = 0.0005, P = 0.019
for time and time squared, respe c t i v e l y ) .  I n  F i g u r e  1 ,  t h e
observed and the model-based estimated absolute values of
triglyceride levels are presented in the logarithmic scale.
Discussion
It is generally accepted that adjuvant hormonal treatment with
tamoxifen has a beneficial effect on serum lipids of postmeno-
pausal breast cancer patients, which is possibly due to its ago-
nistic estrogenic activity. Conversely, the use of AIs has raised
some concerns with respect to lipid profiles because of estro-
gen deprivation caused by aromatase inhibition. However,
considering that exemestane is an irreversible steroidal AI
requiring de novo enzyme synthesis for estrogen synthesis,
exemestane and its metabolites have been suggested to have
a protective effect on lipid metabolism compared with the non-
steroidal aromatase inhibitors [35-37]. The effect of extending
Table 3
Observed changes from baseline values over the study period (mean ± standard error)
6 mo 12 mo 18 mo 24 mo
Mean ± SEM P Mean ± SEM P Mean ± SEM P Mean ± SEM P
Cholesterol change E 11.5 ± 5.6 0.046 14.4 ± 5 0.005 15.3 ± 7 0.037 8.9 ± 7.4 NS
O 16.8 ± 4.7 0.001 21.6 ± 4.1 <0.001 24 ± 5.3 <0.001 17 ± 6 0.009
HDL change E -4.3 ± 1.8 0.025 -3 ± 2.3 NS -6.5 ± 2.6 0.024 -8.3 ± 2.1 0.001
O 2.2 ± 1.5 NS 1.7 ± 1.4 NS 1.5 ± 1.2 NS 1.1 ± 1.9 NS
LDL change E 24.3 ± 6.3 0.001 20.1 ± 6.3 0.004 22.7 ± 9.5 0.030 32.1 ± 8.1 0.001
O 19.8 ± 5.7 0.002 22.3 ± 4.9 <0.001 30.4 ± 6.2 <0.001 23 ± 8.4 0.015
Total TRG change E -24.1 ± 7.8 0.004 -32.2 ± 7.6 <0.001 -26.8 ± 9.3 0.008 -20.7 ± 9.6 0.040
O -13.7 ± 6.1 0.031 -17.6 ± 7.6 0.026 -9.4 ± 7.2 NS -19.8 ± 9 0.038
E = exemestane; O = observation.
Note: t-test P values, NS = nonsignificant when P > 0.05.
Table 4
Estimated differences between treatments of mean absolute values for lipid parameters across the study period according to the 
mixed-effects model (mean ± standard error).
Cholesterol value HDL value LDL value Total TRG value
E-Oa E-O E-Oa E-Oa
Baseline Mean ± SEM -0.25 ± 1.36
P 0.85
6 months Mean ± SEM -2.96 ± 1.07
P 0.01
12 months Mean ± SEM -1.23 ± 2.93 -5.68 ± 1.35 7.77 ± 4.42 -0.02 ± 0.03
P 0.68 <0.0001 0.08 0.50
18 months Mean ± SEM -8.39 ± 1.97
P <0.0001
24 months Mean ± SEM -11.1 ± 2.7
P <0.0001
E = exemestane; O = observation.
aNote: Constant difference between E and O across time.Breast Cancer Research    Vol 11 No 3    Markopoulos et al.
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treatment with exemestane after several years of adjuvant
tamoxifen does not appear to differ significantly from the effect
of tamoxifen deprivation itself, in terms of lipid profile, indicat-
ing that exemestane is not adversely detrimental to lipid
parameters when compared with observation alone.
Our final findings from the ATENA lipid substudy confirm the
protective effect of tamoxifen on the lipid profile and indicate
an overall trend for increasing cholesterol levels after cessa-
tion of tamoxifen in the whole population. Total cholesterol lev-
els increased significantly in both arms, with a more-
pronounced increase in the observation arm, whereas overall,
no difference was found between the two groups. HDL levels
in the exemestane arm seemed to decrease significantly after
the first year of treatment, an effect that was different from that
observed in our preliminary analysis at the end of the 1-year
study period. The initial sharp increase in LDL cholesterol, as
it was reported during our initial report, seems to smooth out
to a smaller increase at 24 months for both groups, whereas
consistency was noted in the finding of lack of significance
between the two treatment groups. Our final results also con-
firm the significant decrease across time in both arms for trig-
lyceride levels. Evidence was noted that lower TRG levels
below the 'threshold' value of about 1.5 mmol/l (133 mg/dl)
will cause a change in the LDL-size profile to larger, less dense
and, therefore, less atherogenic species [38]. In this context,
the statistically significant increase in the LDL levels observed
at 12 months in the group of patients treated with exemestane
should be considered of lesser clinical importance because it
is accompanied by a significant decrease in the TRG levels.
It is rather difficult to assess the impact of AIs on the lipid pro-
file of postmenopausal patients by comparing results of pub-
lished studies because of the different designs of trials.
Tamoxifen was the comparator in most major studies, with the
exception of MA17, in which letrozole was compared with pla-
cebo [9]. Additionally, the results depend on the duration of
therapy and on how the lipid data were collected. However,
our final findings are overall in accordance with results from
other previously published trials regarding the effect of AIs on
lipid profiles.
Figure 1
Estimated mean values versus observed for total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides  (total log TRG) Estimated mean values versus observed for total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides 
(total log TRG).Available online http://breast-cancer-research.com/content/11/3/R35
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In a study by Engan et al. (39), which examined the lipid profile
in patients receiving exemestane or tamoxifen, 12 postmeno-
pausal metastatic breast cancer (MBC) patients received
escalating doses of exemestane (5 to 200 mg/day), and 6
patients received 20 to 30 mg/day tamoxifen; significant
reductions in TC, TRG, HDL, and Apo A1 levels were
observed after 12 weeks of treatment with exemestane. TC
was significantly decreased after 9 weeks of tamoxifen treat-
ment [39]. In another prospective, randomized phase II study,
the EORTC trial 10951, examining serum lipid profiles in post-
menopausal MBC patients, Atalay et al. (40), reported that
exemestane and tamoxifen had opposite effects on TRG lev-
els: exemestane reduced whereas tamoxifen increased TRG
levels over time. In their study of 122 women, lipid parameters
(TC, TRG, HDL, Apo 1, Apo B, and Lip a) were monitored at
8, 24, and 48 weeks of treatment. Apart from TRG and Apo
A1, no other lipid parameters were altered during the study for
either treatment arm. The authors concluded that because
their population was relatively small and many patients did not
have data at the later time points, a larger population should
be studied to confirm the results. Hypercholesterolemia was
not reported in the IES trial of sequential exemestane after
tamoxifen [8,32].
In another study examining the lipid profiles in 55 postmeno-
pausal women with early breast cancer who switched to
exemestane after at least 2 years of tamoxifen treatment, trig-
lycerides and HDL cholesterol significantly decreased in the
exemestane group, whereas LDL cholesterol significantly
increased at the end of the 1-year study period [41]. Those
results are consistent with ours observed in the 12-month
analysis of our data; however, the different duration of our
study gives the opportunity for observations for a longer period
when the effect of the foregone tamoxifen treatment is lost
(29). The sharp increase in LDL levels observed during the first
year of the study, similar for both arms, seems to smooth out
to smaller mean values during the second year (Table 4 and
Figure 1), and it is most likely to represent LDL changes in the
lipid profiles of healthy postmenopausal women, whereas the
diverse change of HDL levels across time in the two arms of
the study (Figure 1) is indicative of a trend for decreased HDL
levels in patients with long-term exemestane treatment.
In a placebo-controlled study involving 147 postmenopausal
women with early breast cancer, exemestane had no major
effect on the lipid profile except for a modest but significant
decrease from baseline in HDL cholesterol (P < 0.001) and
apolipoprotein A1 [42]. Results from the TEAM (Tamoxifen
and Exemestane Adjuvant Multicenter) trial lipid substudy con-
ducted by our group suggested a trend for a reduction in total
cholesterol in both treatment arms, whereas TC and LDL con-
sistently and significantly decreased in the tamoxifen arm only.
The mean HDL level was higher for the tamoxifen arm com-
pared with the exemestane arm across time. No significant
trend was detected throughout the study period on triglycer-
ide levels in either arm [43,44].
In terms of the other two extended adjuvant AI trials, our find-
ings are consistent with those of the letrozole MA.17 lipid sub-
study results. According to this, letrozole had no significant
effect on the lipid profiles of 347 postmenopausal women
after 36 months of treatment. Both treatment arms experi-
enced increases in total cholesterol, LDL, and triglycerides at
6 months, but this could be perceived as a consequence of
the discontinuation of tamoxifen. Levels later leveled off and
remained fairly stable [45]. In an extension of the MA.17 study
currently under way, patients are being rerandomized to an
additional 5 years of letrozole or placebo. Data from this group
could allow further investigation of the lipid and cardiovascular
effects that may occur with long-term estrogen deprivation.
Adjuvant trials comparing aromatase inhibitors with tamoxifen
have also provided evidence of the effect of AIs on lipid metab-
olism. When comparing tamoxifen therapy with each AI results
in some changes in lipid parameter levels, but again, no detri-
mental effects have been observed. These effects could be
due to the beneficial effect of tamoxifen mainly and, to a lesser
extent, to the adverse effect of AI therapy.
Initial results of the LEAP trial directly compare safety parame-
ters between the steroidal AI exemestane and the nonsteroidal
AIs anastrozole and letrozole in 90 healthy postmenopausal
women [46]. Initial results show that no significant differences
exist between anastrozole and letrozole in effects on LDL/HDL
ratios, triglyceride concentrations, and non-HDL concentra-
tions. Exemestane was associated with an increase in the
LDL/HDL ratio (+17) (P = 0.047) compared with anastrozole.
No median change from baseline is seen in total serum choles-
terol for letrozole, a slight increase for anastrozole (+0.4), and
a nonsignificant decrease for exemestane (-3.9) (P = 0.164 vs.
anastrozole).
Current data do not allow drawing any clear conclusions about
the effects of AIs on lipid metabolism. However, one must note
that AIs lack the cardioprotective effect of tamoxifen. Moreo-
ver, most of the trials published today provide data for a follow-
up to a maximum of 3 years of treatment. No clear evidence is
found of the long-term effect of AIs on lipid parameters and
subsequently on cardiovascular health as a whole. However,
the benefits of receiving an AI are likely to outweigh the risk of
the effect on lipid profiles.
Conclusions
Our results are in agreement with those of previously pub-
lished AI lipid trials. Exemestane does not have the protective
effect of tamoxifen on lipids. A trend for decreased HDL levels
was noticed across time in patients with long-term exemes-
tane treatment. However, extended adjuvant treatment with
exemestane in postmenopausal breast cancer patients afterBreast Cancer Research    Vol 11 No 3    Markopoulos et al.
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cessation of 5 to 7 years of tamoxifen does not appear overall
to alter significantly the lipid profile compared with that of an
observational arm.
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